Hepatitis Monthly

Published by: Kowsar

IgG4 Status in Explanted Livers Does Not Affect the Outcome of Primary Sclerosing Cholangitis (PSC) After Liver Transplant

Bandar Al-Judaibi 1 , 2 , * , Roberto Hernandez-Alejandro 2 , Chaturika Herath 3 , Subrata Chakrabarti 3 , M. Katherine Dokus 2 , Paul Marotta 1 and Mansour Alghanem 1
Authors Information
1 Division of Gastroenterology, Department of Medicine, Western University, Ontario, Canada
2 Division of Transplant, University of Rochester, Rochester, New York, United States of America
3 Department of Pathology, Western University Ontario, Ontario, Canada
Article information
  • Hepatitis Monthly: July 2018, 18 (7); e66037
  • Published Online: June 12, 2018
  • Article Type: Research Article
  • Received: January 8, 2018
  • Revised: April 29, 2018
  • Accepted: May 1, 2018
  • DOI: 10.5812/hepatmon.66037

To Cite: Al-Judaibi B, Hernandez-Alejandro R, Herath C, Chakrabarti S, Dokus M K, et al. IgG4 Status in Explanted Livers Does Not Affect the Outcome of Primary Sclerosing Cholangitis (PSC) After Liver Transplant, Hepat Mon. 2018 ;18(7):e66037. doi: 10.5812/hepatmon.66037.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Lindor KD, Kowdley KV, Harrison ME, American College of G. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646-59. quiz 660. doi: 10.1038/ajg.2015.112. [PubMed: 25869391].
  • 2. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25(6):727-39. doi: 10.1016/j.bpg.2011.10.009. [PubMed: 22117638]. [PubMed Central: PMC3236286].
  • 3. Beuers U, Hubers LM, Doorenspleet M, Maillette de Buy Wenniger L, Klarenbeek PL, Boonstra K, et al. IgG4-Associated Cholangitis--A Mimic of PSC. Dig Dis. 2015;33 Suppl 2:176-80. doi: 10.1159/000440830. [PubMed: 26641633].
  • 4. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51. doi: 10.1056/NEJMra1104650. [PubMed: 22316447].
  • 5. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013;7(2):103-14. doi: 10.1586/egh.12.80. [PubMed: 23363260].
  • 6. Nishino T, Oyama H, Hashimoto E, Toki F, Oi I, Kobayashi M, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol. 2007;42(7):550-9. doi: 10.1007/s00535-007-2038-8. [PubMed: 17653651].
  • 7. Esposito I, Born D, Bergmann F, Longerich T, Welsch T, Giese NA, et al. Autoimmune pancreatocholangitis, non-autoimmune pancreatitis and primary sclerosing cholangitis: a comparative morphological and immunological analysis. PLoS One. 2008;3(7). e2539. doi: 10.1371/journal.pone.0002539. [PubMed: 18596913]. [PubMed Central: PMC2440515].
  • 8. Kawa S, Hamano H, Umemura T, Kiyosawa K, Uehara T. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res. 2007;37 Suppl 3:S487-95. doi: 10.1111/j.1872-034X.2007.00235.x. [PubMed: 17931208].
  • 9. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070-5. doi: 10.1111/j.1572-0241.2006.00772.x. [PubMed: 16879434].
  • 10. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114(1):53-64. doi: 10.1093/bmb/ldv019. [PubMed: 25981516].
  • 11. Mendes F, Lindor KD. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol. 2010;7(11):611-9. doi: 10.1038/nrgastro.2010.155. [PubMed: 20938459].
  • 12. Chen JH, Deshpande V. IgG4-related Disease and the Liver. Gastroenterol Clin North Am. 2017;46(2):195-216. doi: 10.1016/j.gtc.2017.01.001. [PubMed: 28506361].
  • 13. Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34(1):88-94. doi: 10.1097/PAS.0b013e3181c6c09a. [PubMed: 20035148].
  • 14. Deshpande V. The pathology of IgG4-related disease: critical issues and challenges. Semin Diagn Pathol. 2012;29(4):191-6. doi: 10.1053/j.semdp.2012.08.001. [PubMed: 23068297].
  • 15. Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42. doi: 10.1007/s00534-012-0521-y. [PubMed: 22717980].
  • 16. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2010;30(2):222-31. doi: 10.1111/j.1478-3231.2009.02092.x. [PubMed: 19650840].
  • 17. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/modpathol.2012.72. [PubMed: 22596100].
  • 18. Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol. 2012;26(5):261-8. [PubMed: 22590699]. [PubMed Central: PMC3352841].
  • 19. Al-Judaibi B, Hernandez Alejandro R, Uhanova J, Marotta P, Mosli M, Chandok N. Duct-to-Duct Biliary Anastomosis Yields Similar Outcomes to Roux-en-Y Hepaticojejunostomy in Liver Transplantation for Primary Sclerosing Cholangitis. Hepat Mon. 2015;15(5). e18811. doi: 10.5812/hepatmon.15(5)2015.18811. [PubMed: 26045700]. [PubMed Central: PMC4451269].
  • 20. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29(4):1050-6. doi: 10.1002/hep.510290427. [PubMed: 10094945].
  • 21. Gelley F, Zadori G, Gorog D, Kobori L, Fehervari I, Gaman G, et al. Recurrence of primary sclerosing cholangitis after liver transplantation - The Hungarian experience. Interv Med Appl Sci. 2014;6(1):16-8. doi: 10.1556/IMAS.6.2014.1.2. [PubMed: 24672670]. [PubMed Central: PMC3955810].
  • 22. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330-40. doi: 10.1002/lt.21679. [PubMed: 19243003].
  • 23. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139-46. doi: 10.1016/j.jhep.2015.07.005. [PubMed: 26186988].
  • 24. Fischer S, Trivedi PJ, Ward S, Greig PD, Therapondos G, Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol. 2014;95(3):209-15. doi: 10.1111/iep.12076. [PubMed: 24750423]. [PubMed Central: PMC4351857].
  • 25. Bjornsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18(3):198-205. doi: 10.1097/MJT.0b013e3181c9dac6. [PubMed: 20228674].
  • 26. Hamano H, Umemura T, Uehara T, Kawa S, Kiyosawa K. IgG4-related sclerosing cholangitis should be included as an exclusion criterion for the diagnosis of primary sclerosing cholangitis. Am J Gastroenterol. 2007;102(3):691-2. doi: 10.1111/j.1572-0241.2007.01040_8.x. [PubMed: 17335458].
  • 27. Doorenspleet ME, Hubers LM, Culver EL, Maillette de Buy Wenniger LJ, Klarenbeek PL, Chapman RW, et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology. 2016;64(2):501-7. doi: 10.1002/hep.28568. [PubMed: 27015613]. [PubMed Central: PMC5017301].
  • 28. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706-15. doi: 10.1053/j.gastro.2007.12.009. [PubMed: 18222442].
  • 29. Oh HC, Kim MH, Lee KT, Lee JK, Moon SH, Song TJ, et al. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(12):1831-7. doi: 10.1111/j.1440-1746.2010.06411.x. [PubMed: 21091993].
  • 30. Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59(5):1954-63. doi: 10.1002/hep.26977. [PubMed: 24375491]. [PubMed Central: PMC4489327].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments